RxDoctor Payments Data

Leah Carrington, APRN

Family · Rogers, ARNPI 1629453030

Payments from drug & device makers

What this record shows

This record is dominated by other: $1,619,276 of the $1,619,751 with a category attached, or 100.0%. Skye Orthobiologics LLC accounts for 100.0% of it on its own, with 10 other manufacturers making up the rest. 2024 is the largest year on record at $1,619,310, more than ten times the $14 reported in 2021. Among family clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,619,751in general payments, 2019–2025

Across 17 payments — averaging $95,279 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Skye Orthobiologics LLC$1.6M
  • Dexcom, Inc.$138
  • Abbott$118
  • KCI USA, Inc.$50
  • Smith+Nephew$44
  • Lundbeck LLC$40
  • plus $86 from 5 others

What the payments were for

  • Food & beverage$4760%
  • Other$1,619,276100%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,619,751 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$42,837
Medicare patients
24
Services billed
294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tresiba Flextouch U-200Insulin Degludec13$11,850
Fluticasone Propionate11$213

Paid to pharmacies, not to this prescriber.

Other family in Rogers

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →